Otsuka Pharmaceutical Co. Ltd.’s new alliance with US venture Click Therapeutics Inc. is aimed at developing and commercializing a novel prescription “digital therapeutic” for major depressive disorder, as part of the Japanese firm’s ongoing foray into digital health approaches and strategic focus on the mental health area.
The main goal is to provide an effective new tool to support the management of the highly debilitating condition, one that could be used either as an adjunct to standard drug and other therapy, or potentially by
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?